<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl1" position="float">
 <label>Table 1</label>
 <caption>
  <title>List of the Representative Formulations Used for Vaccines</title>
 </caption>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col/>
   <col/>
   <col/>
   <col/>
   <col/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">materials</th>
    <th style="border:none;" align="center">formulations</th>
    <th style="border:none;" align="center">cargos (vaccine types)</th>
    <th style="border:none;" align="center">functions</th>
    <th style="border:none;" align="center">refs</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="5" style="border:none;" valign="middle">lipids</td>
    <td style="border:none;">ionizable lipid</td>
    <td style="border:none;">mRNA (glycoprotein 100 (gp100) and tyrosinase-related protein 2 (TRP 2)) and adjuvants lipopolysaccharide (LPS)</td>
    <td style="border:none;">stabilization, enhanced cellular uptake</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref54">54</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">covalently cross-linked lipid bilayers</td>
    <td style="border:none;">protein/adjuvants (Monophosphoryl lipid A (MPLA))</td>
    <td style="border:none;">stabilization, sustained delivery, co-delivery</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref55">55</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">net negative charged formulations by tuning cationic lipids and mRNA ratio</td>
    <td style="border:none;">mRNA (influenza virus hemagglutinin (HA) and OVA)</td>
    <td style="border:none;">LN targeting, stabilization</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref56">56</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">nanodiscs 
     <italic>via</italic> sHDL
    </td>
    <td style="border:none;">peptide neoantigens/adjuvants (CpG); dual adjuvants (CpG and MPLA)</td>
    <td style="border:none;">co-delivery, enhanced uptake</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref57">57</xref>, 
     <xref ref-type="bibr" rid="ref58">58</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">lipids with cyclic amino headgroup</td>
    <td style="border:none;">mRNA (OVA and E7)</td>
    <td style="border:none;">immunostimulatory function</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref59">59</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="10" style="border:none;" valign="middle">polymers</td>
    <td style="border:none;">modified dendrimer</td>
    <td style="border:none;">mRNA (H1N1 influenza, Ebola viruses, and 
     <italic>Toxoplasma gondii</italic> parasite)
    </td>
    <td style="border:none;">enhanced loading, cellular uptake, and endosomal release</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref60">60</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">stearic acid conjugated low MW PEI</td>
    <td style="border:none;">peptide (TRP 2) and mRNA (HIV-1)</td>
    <td style="border:none;">lowered charge density, higher biocompatibility</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref61">61</xref>, 
     <xref ref-type="bibr" rid="ref62">62</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">cyclodextrin conjugated PEI</td>
    <td style="border:none;">mRNA (HIV)</td>
    <td style="border:none;">lowered charge density, higher biocompatibility</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref63">63</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">PLGA NPs</td>
    <td style="border:none;">protein (OVA)</td>
    <td style="border:none;">controlled antigen release</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref64">64</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">PEI/chitosan/poly lysine coated PLGA/PLA</td>
    <td style="border:none;">protein (HBV surface antigen)</td>
    <td style="border:none;">enhanced loading and cellular uptake, intrinsic immunostimulatory function</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref65">65</xref>−
     <xref ref-type="bibr" rid="ref67">67</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">PBAE and PLGA</td>
    <td style="border:none;">plasmid DNA (Luciferase)</td>
    <td style="border:none;">enhanced loading and lower cytotoxicity</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref68">68</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">ionizable amino polyester</td>
    <td style="border:none;">mRNA (luciferase)</td>
    <td style="border:none;">spleen targeting</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref69">69</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">oligopeptide-modified PBAE</td>
    <td style="border:none;">mRNA (enhanced green fluorescent protein)</td>
    <td style="border:none;">APC targeting</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref70">70</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">albumin and albumin-binding lipids</td>
    <td style="border:none;">peptide (OVA) /adjuvant (CpG)</td>
    <td style="border:none;">LN targeting</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref71">71</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">polysaccharide from microbial cell wall and PEI</td>
    <td style="border:none;">mRNA (OVA)</td>
    <td style="border:none;">immunostimulatory, enhanced loading and endosomal release</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref72">72</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="7" style="border:none;" valign="middle">inorganic particles</td>
    <td style="border:none;">aluminum hydroxide</td>
    <td style="border:none;">phosphoserine conjugated protein antigen (HIV trimer)</td>
    <td style="border:none;">immunostimulatory, sustained release</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref73">73</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">chemically functionalized Au NPs with hydrophobicity</td>
    <td style="border:none;">–</td>
    <td style="border:none;">intrinsic immunostimulatory function</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref74">74</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">aspect ratio optimized and surface modified Au NRs</td>
    <td style="border:none;">plasmid DNA (HIV-1)</td>
    <td style="border:none;">enhanced cellular uptake, intrinsic immunostimulatory function</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref75">75</xref>, 
     <xref ref-type="bibr" rid="ref76">76</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">sized optimized Au NPs</td>
    <td style="border:none;">peptide (OVA) and adjuvant (CpG)</td>
    <td style="border:none;">enhanced DC activation</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref77">77</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">mesoporous Si NPs</td>
    <td style="border:none;">adjuvant; protein (E2 of diarrhea virus)</td>
    <td style="border:none;">intrinsic immunostimulatory function</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref78">78</xref>, 
     <xref ref-type="bibr" rid="ref79">79</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">antigen density tunable/Size controllable QDs</td>
    <td style="border:none;">peptide (self-antigen from multiple sclerosis)</td>
    <td style="border:none;">LN homing and higher density of antigens leads to more effective tolerance, intrinsic antiviral effects</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref80">80</xref>, 
     <xref ref-type="bibr" rid="ref81">81</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;">oxidized multiwalled CNTs</td>
    <td style="border:none;">protein (NY-ESO-1) and adjuvant (CpG)</td>
    <td style="border:none;">co-delivery, enhanced uptake</td>
    <td style="border:none;">(
     <xref ref-type="bibr" rid="ref82">82</xref>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
